09 7月 2024 by admin in UncategorizedComments nterius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
01 7月 2024 by admin in UncategorizedComments Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer July 1, 2024
15 5月 2024 by admin in UncategorizedComments Sail Biomedicines Appoints Clinical and Scientific Leader Dr. Wendy Chung to Its Board
15 5月 2024 by admin in UncategorizedComments Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
13 5月 2024 by admin in UncategorizedComments RareStone Group Announces Appointment of Andy Zhang and Hardy Huan as Co-CEOs
07 5月 2024 by admin in UncategorizedComments Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
06 5月 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid Tumors
